Literature DB >> 11735675

Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions.

J E Batista-Miranda1, M D Diez, P A Bertrán, H Villavicencio.   

Abstract

A literature search was conducted to review quality-of-life (QOL) measurement in patients with benign prostatic hypertrophy (BPH). The different QOL instruments are discussed in relation to their correlation with symptom evaluation in studies of treatment options for BPH. Symptom evaluation of BPH has been standardised internationally with the International Prostatic Symptom Score (IPSS), but there is neither agreement nor data to decide which QOL instrument is preferable. The most widely used QOL instrument is the disease-specific QOL single question added to the IPSS. Other QOL instruments have been used, but none has gained unanimous approval. The results of QOL assessments obtained from comparative clinical studies of treatment options for BPH are discussed. These studies compare treatment options such as watchful waiting, drug treatment and surgery. Disease-specific QOL domains (interference with daily activities) tend to improve more with treatment interventions than general health measures (i.e. general well-being). The use of QOL instruments to evaluate patients with BPH, and their many treatment options, is still open to debate with regard to which instruments are preferred and their importance to the clinical evaluation of the patient. The challenge remains to find an acceptable disease-specific QOL instrument that adds information to currently used disease measures of BPH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11735675     DOI: 10.2165/00019053-200119110-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  52 in total

Review 1.  The measurement of symptoms, quality of life and sexual function.

Authors:  J L Donovan
Journal:  BJU Int       Date:  2000-03       Impact factor: 5.588

2.  Improved indication and followup in transurethral resection of the prostate using the computer program CLIM: a prospective study.

Authors:  H J Rollema; R Van Mastrigt
Journal:  J Urol       Date:  1992-07       Impact factor: 7.450

Review 3.  Measuring quality of life in clinical trials: a taxonomy and review.

Authors:  G H Guyatt; S J Veldhuyzen Van Zanten; D H Feeny; D L Patrick
Journal:  CMAJ       Date:  1989-06-15       Impact factor: 8.262

4.  Validation of a symptoms questionnaire for benign prostatic hyperplasia.

Authors:  J A Bolognese; R C Kozloff; S C Kunitz; P B Grino; D L Patrick; E Stoner
Journal:  Prostate       Date:  1992       Impact factor: 4.104

5.  Interstitial laser coagulation for management of benign prostatic hyperplasia: a Japanese experience.

Authors:  Y Arai; K Okubo; T Okada; S Maekawa; Y Aoki; H Maeda
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

6.  Relief of BPO or improvement in quality of life?

Authors:  P Teillac
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

7.  Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group.

Authors:  J L Tenover; G A Pagano; A S Morton; C L Liss; C A Byrnes
Journal:  Clin Ther       Date:  1997 Mar-Apr       Impact factor: 3.393

8.  Holmium laser resection v transurethral resection of the prostate: results of a randomized trial with 2 years of follow-up.

Authors:  P J Gilling; K M Kennett; M R Fraundorfer
Journal:  J Endourol       Date:  2000-11       Impact factor: 2.942

9.  Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar.

Authors:  C A Byrnes; A S Morton; C L Liss; M C Lippert; J Y Gillenwater
Journal:  Clin Ther       Date:  1995 Sep-Oct       Impact factor: 3.393

10.  Transurethral electrovaporization of the prostate--a possible alternative to transurethral resection: a one-year follow-up of a prospective randomized trial.

Authors:  M Y Hammadeh; G A Fowlis; M Singh; T Philp
Journal:  Br J Urol       Date:  1998-05
View more
  7 in total

1.  Validity of the "bother score" in the evaluation and treatment of symptomatic benign prostatic hyperplasia.

Authors:  Michael P O'leary
Journal:  Rev Urol       Date:  2005

2.  IPSS "bother question" score predicts health-related quality of life better than total IPSS score.

Authors:  Florin V Hopland-Nechita; John R Andersen; Christian Beisland
Journal:  World J Urol       Date:  2022-01-09       Impact factor: 4.226

3.  Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction.

Authors:  Petros Sountoulides; Marleen M van Dijk; Hessel Wijkstra; Jean J M C H de la Rosette; Martin Christian Michel
Journal:  World J Urol       Date:  2009-10-09       Impact factor: 4.226

Review 4.  Measurement of benign prostatic hyperplasia treatment effects on male sexual function.

Authors:  T A Skolarus; J T Wei
Journal:  Int J Impot Res       Date:  2009-06-18       Impact factor: 2.896

5.  Health seeking behavior for lower urinary tract symptoms in black men.

Authors:  Aruna V Sarma; Lauren Wallner; Steven J Jacobsen; Rodney L Dunn; John T Wei
Journal:  J Urol       Date:  2008-05-21       Impact factor: 7.450

Review 6.  Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials.

Authors:  Jayne E Edwards; R Andrew Moore
Journal:  BMC Urol       Date:  2002-12-12       Impact factor: 2.264

7.  Real-world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain.

Authors:  José María Molero; Bernardino Miñana; Juan Manuel Palacios-Moreno; Miguel Téllez Martínez-Fornes; David Lorite Mingot; Alfonso Agra Rolán; Ágata Carreño; Rafael Cuervo Pinto
Journal:  Int J Clin Pract       Date:  2020-08-16       Impact factor: 3.149

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.